We are live on ! Find out more
EDIT icon

Editas Medicine

196 hedge funds and large institutions have $51M invested in Editas Medicine in 2025 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 44 increasing their positions, 61 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

97% more call options, than puts

Call options by funds: $668K | Put options by funds: $339K

5% less funds holding

Funds holding: 207 → 196 (-11)

8.81% less ownership

Funds ownership: 61.84% → 53.03% (-8.8%)

28% less repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 61

29% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 34

47% less capital inflows, than outflows

Capital inflows: $10.6M | Capital outflows: $19.8M

Holders
196
Holders Change
-11
Holders Change %
-5.31%
% of All Funds
2.62%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
44
Reduced
61
Closed
34
Calls
$668​K
Puts
$339​K
Net Calls
+$329​K
Net Calls Change
+$321​K

EDIT Hedge Fund Activity: Q1 2025 in Review

196 of the 7,490 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q1 2025, worth a combined $51M — down 21% from $64.8M a quarter earlier.

Sellers outnumbered buyers: 34 funds closed out of EDIT and 24 opened new positions — a net loss of 10 holders — while 61 trimmed existing stakes and 44 added.

The largest buyer was UBS AM, adding an estimated $2.1M. The largest seller was Millennium Management, cutting an estimated $3.62M.

  • 196 institutional investors held Editas Medicine (EDIT) as of Q1 2025, down from 207 in Q4 2024.
  • Funds reported $51M of Editas Medicine stock for Q1 2025, down 21% quarter-over-quarter.
  • 24 funds opened new Editas Medicine positions in Q1 2025 and 34 closed out, a net change of -10 holders.
  • The largest Editas Medicine buyer in Q1 2025 was UBS AM, an estimated $2.1M added.
  • The largest Editas Medicine seller in Q1 2025 was Millennium Management, an estimated $3.62M sold.

Based on aggregated 13F filings for Q1 2025.